Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity.
about
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT.Development of an automated analysis system for data from flow cytometric intracellular cytokine staining assays from clinical vaccine trials.Peptide impurities in commercial synthetic peptides and their implications for vaccine trial assessmentCryopreservation-related loss of antigen-specific IFNγ producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy.Optimal auxiliary-covariate-based two-phase sampling design for semiparametric efficient estimation of a mean or mean difference, with application to clinical trialsHuman immunodeficiency virus-specific responses in adult Ugandans: patterns of cross-clade recognition.Human immunodeficiency virus (HIV)-specific gamma interferon secretion directed against all expressed HIV genes: relationship to rate of CD4 decline.Enhanced cellular immunity in macaques following a novel peptide immunotherapy.Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness costEquivalence of ELISpot assays demonstrated between major HIV network laboratoriesHV-1-specific cytotoxic T lymphocytes and breast milk HIV-1 transmissionThe External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assayEstablishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials.The immune space: a concept and template for rationalizing vaccine development.Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer stainingPhase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.Use of RT-defective HIV virions: new tool to evaluate specific response in chronic asymptomatic HIV-infected individualsLatent tuberculosis detection by interferon γ release assay during pregnancy predicts active tuberculosis and mortality in human immunodeficiency virus type 1-infected women and their childrenGuidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories.Evaluation of the interlaboratory concordance in quantification of human immunodeficiency virus-specific T cells with a gamma interferon enzyme-linked immunospot assayA trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1.Induction of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses in HIV vaccine trial participants who subsequently acquire HIV-1 infection.Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells.Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution.Consistency of Mycobacterium tuberculosis-specific interferon-gamma responses in HIV-1-infected women during pregnancy and postpartum.Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study.Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials.Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials.Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized.Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trialA dual color ELISPOT method for the simultaneous detection of IL-2 and IFN-gamma HIV-specific immune responses.Optimization and qualification of an 8-color intracellular cytokine staining assay for quantifying T cell responses in rhesus macaques for pre-clinical vaccine studies.Defining ELISpot cut-offs from unreplicated test and control wells.Variability of the IFN-γ ELISpot assay in the context of proficiency testing and bridging studiesGamma interferon-mediated inflammation is associated with lack of protection from intravaginal simian immunodeficiency virus SIVmac239 challenge in simian-human immunodeficiency virus 89.6-immunized rhesus macaquesConcordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents.Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.Multiple T-cell responses to human immunodeficiency virus type 1 are enhanced by dendritic cells
P2860
Q30444086-B35BC675-D541-46F3-B307-D6E248F6AC1AQ30484153-74A742D4-E7E0-461A-99BB-A31E05007B87Q31162124-AF533ACD-CB1B-4679-99A4-E444B3656DDEQ33310152-0284B6D5-4298-478C-967D-EECFDDDEAE98Q33551527-09E0A002-E19A-480E-B176-9A7339D6388EQ33611244-A23210D9-3887-490B-A2FC-E99EF3848EFFQ33707543-2ECE7D90-8251-4E4F-BEBF-932E511B7696Q33724256-D4527884-77FC-4635-8172-C1627FE06291Q33737787-371C4F26-812E-4EE1-99B1-84141DCFCD54Q33754974-EB4B95B5-F76D-41A8-9EAB-C324343A2A89Q33778327-EF61FB71-AAEB-4B22-A0D7-B473D33602EBQ33936741-556E6541-3B08-44B3-92B4-6B8309240132Q34066932-3ECFF635-D15A-48B8-AAF4-DEC763659BDCQ34125277-C17C85A5-284F-4CCC-A2C1-5B5A919E1DD9Q34399762-F5B60BF0-356B-4F60-8E1C-4DCBFB6D9BC4Q34402469-75B890E5-DE7B-40E6-B0DA-76A5D8FA52C8Q34592982-CC3AFF6F-10F1-4F59-9162-F9C81B341533Q34630184-CDE22AE5-8240-4E1B-91F0-F1A3748FF970Q34678691-9B05A7DC-056B-4DC6-BBDF-6D2439B8053FQ34718060-1765BC60-B787-4FA3-B7B5-FB1242DE05B2Q34720316-A3A802CA-25F5-4CAD-ADDE-8A321DCD0F9DQ34743297-C86D02D6-58B1-4F89-9D2D-07A07DCAF057Q34789269-CFA416F6-88DE-4B30-BD3C-FA527D064AFCQ35101431-70EE599A-7B22-4C18-A604-61A7C938885BQ35104509-F948C607-12D6-4F70-AD8C-7422153F5A56Q35634318-33281916-2F2D-4B56-BB84-773DD077DC27Q35852451-0B50084A-3D45-486A-AF4A-A0B3539F25C0Q35863376-1238D214-4B15-4F9F-A3AD-BCD1D42F63AFQ35865556-2F89D5DF-289E-4AA4-B9FC-D0DAF7344C74Q35919760-3A4DEB17-0E86-4D9C-B850-1F20C720F70AQ36473740-46109277-ACCC-4B6C-9CC1-CCFBFBC2235EQ36618096-7A366B54-EFD5-4AA8-B3CD-A3C0AC0B2520Q36769107-64174761-4EAC-4C9B-86EC-93BBAD0AA829Q36822332-67EA33ED-D5CE-426C-9808-B4AEA3B55A18Q36852775-98678B93-D14B-477B-A2CB-F362EF6007EFQ36880258-68898DE9-9D4D-4844-82F4-7FE3550512E7Q36942556-E9DC3477-5471-4B6F-AE50-640EC8B418F7Q37099271-E1343FF9-BE93-4AFE-B6A8-D6FDACCA1351Q37216571-B8066735-A28A-42FD-A0F5-4899839B3A1FQ37374667-6A083FC6-B6D7-40F8-9F89-92008BCB97FF
P2860
Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Moving to human immunodeficien ...... ential correlates of immunity.
@en
Moving to human immunodeficien ...... ential correlates of immunity.
@nl
type
label
Moving to human immunodeficien ...... ential correlates of immunity.
@en
Moving to human immunodeficien ...... ential correlates of immunity.
@nl
prefLabel
Moving to human immunodeficien ...... ential correlates of immunity.
@en
Moving to human immunodeficien ...... ential correlates of immunity.
@nl
P2093
P356
P1476
Moving to human immunodeficien ...... ential correlates of immunity.
@en
P2093
Michael G Hudgens
Nina D Russell
Richard Ha
P304
P356
10.1086/367702
P407
P577
2003-01-06T00:00:00Z